The COVID-19 Pandemic – News and Features

A vaccine under development at the University at Buffalo has demonstrated complete protection in mice against a deadly variant of the virus that causes bird flu.

Research from the Keck School of Medicine has found that COVID-19 therapies cause few serious side effects, based on an evaluation of the full spectrum of evidence available from U.S. biomedical science.

The persistent higher rate of alcohol deaths in England since the pandemic in 2020 is an “acute crisis” requiring urgent action from the government, according to a new study led by researchers at UCL and the University of Sheffield.

Discover how microbial biotechnology could reduce suffering and support global health goals, as experts call for awareness and greater investment in innovation.

Scientists have designed new drug frameworks that selectively target CYP3A4, one of the most critical CYP proteins. Structural insights from this work offer a roadmap for future drug developers to better evaluate drug interactions.

Rodents fed a diet rich in soluble fiber coped better with a microorganism that causes diarrhea and can lead to death in debilitated patients. Researchers observed that acetate helps modulate the immune response.

The world-first study found mice treated with the antiviral compound, developed by a multidisciplinary research team at WEHI, were protected from long-term brain and lung dysfunction – key symptoms of long COVID.

Three-dimensional models allow researchers to better represent complex tissues and cell-cell interactions. This article explores the cell models currently used by researchers to understand disease and aid drug discovery.

Researchers have pioneered an influenza virus vector-based nasal spray vaccine platform and developed a nasal spray H5N1 avian influenza vaccine, which has shown promise in animal models.

Antiviral medications nirmatrelvir/ritonavir (Paxlovid) were not effective in relieving long COVID symptoms, according to a phase 2 investigational new drug clinical trial.